Staging and prognosis
. The median survival at diagnosis varies between 2 and >10 years according to the initial stage of the disease. Two clinical staging systems are used. In Europe, the Binet staging system is generally more accepted. It separates three groups of different prognosis ( Table 1) . . In younger patients ( < _ 65 years, physically active, no major health problems) purine analogues may be recommended as initial treatment, because they achieve a higher rate of complete remissions and a longer progression-and treatment-free survival than chlorambucil. The risks and benefits of fludarabine are better documented than those of other purine analogues. Combinations of purine analogues with other drugs, in particular cyclophosphamide appear to result in a higher complete remission rate than single agent therapy, but with a higher toxicity. . In older patients (>65 years, with high comorbidity) chlorambucil can be given as first line therapy, because it is less myelotoxic and immunosuppressive than purine analogues thus resulting in fewer infections.
Second-line chemotherapy 
